The Life Sciences team at Goodwin has advised Gubra A/S ("Gubra") on a license agreement with AbbVie to develop a potential best-in-class, long-acting amylin analog for the treatment of obesity. Gubra is a company listed on Nasdaq Copenhagen specialising in preclinical research services and peptide-based drug discovery within metabolic and fibrotic diseases. This partnership marks AbbVie's entrance into the obesity field. GUB014295 is currently in a Phase 1 clinical trial for the treatment of obesity, and under the license agreement AbbVie will obtain global rights to develop and commercialize GUB014295. The transaction closure is subject to regulatory approvals and other customary closing conditions. Gubra will receive USD 350 million in total upfront payment and will be eligible to receive up to USD 1.875 billion in development, commercial and sales milestone payments, in addition to tiered royalties on global net sales. Goodwin is proud to have advised Gubra on this strategically important transaction.